1. Introduction {#s0005}
===============

Cardiovascular diseases such as coronary heart disease, cerebrovascular disease, atherothrombosis, ischemic heart disease, and peripheral arterial disease are found to be prevalent among different age groups of people especially among the young generation. According to a report by Saquib et al., the death rate from cardiovascular diseases (CVD) would be 4 times higher in 2010 and 21 times higher in 2025 compared to its corresponding rate in 2003 ([@b0055]). Hypertension and dyslipidemia are important, modifiable cardiovascular (CV) risk factors that frequently coexist, and together have an effect on CV risk that may be greater than expected from the simple addition of the risk associated with each condition ([@b0020]).

2. Need of combination therapy {#s0010}
==============================

Novel drug delivery systems are constantly being developed for various purposes such as the expansion of markets and indications, the extension of product life cycles, or the generation of opportunities. Even after advancement in the management of cardiovascular diseases (CVD) during the last several years, they are still the main cause for morbidity and mortality ([@b0030]). Many hypertensive symptoms of hyperlipidemic patients may be reduced using the combination formulation of antihyperlipidemic and antihypertensive agents. Combined dosage form of two or more drugs has been proven useful in multiple therapies as they offer better patient compliance than a single drug. It is well recognized that a single drug, even when used in maximal recommended dosage will control no more than 50% of a hypertensive population ([@b0060]). On the other hand, the skillful use of two or more agents in combination can improve hypertension control rates to well above 80% ([@b0060]). Therefore, the rational for combination therapy is to encourage the use of lower doses of drug to reduce patient's blood pressure with the goal to minimize dose dependent side effects and adverse reactions ([@b0005]). The fixed-dose combination containing the antihypertensive agent amlodipine and the cholesterol lowering agent atorvastatin is the first combination of its kind designed to treat two risk factors for cardiovascular disease ([@b0015]). Atorvastatin has rapid access to non-hepatic tissues due to the hydrophobicity which results in some undesirable side effects. These unwanted side effects associated with combined dosage of atorvastatin and amlodipine may be reduced when rosuvastatin is used in place of atorvastatin. An assortment of techniques has been described for the quantification of rosuvastatin alone or in combination with other products ([@b0030]). The reverse phase-high performance liquid chromatography (RP-HPLC) methods described for simultaneous determination of rosuvastatin and amlodipine in pharmaceutical preparations ([@b0010], [@b0065]) however, is not developed for *in vitro* dissolution profile of rosuvastatin calcium and amlodipine besylate from their combination drug products. Since no systemic studies on the design and development of such a combination formulation or its *in vitro* dissolution study are currently available in literature, we took an attempt to develop a suitable formulation and assay method which can be used further to characterize the *in vitro* dissolution profile of rosuvastatin calcium and amlodipine besylate. Therefore, a simple, accurate, efficient and reproducible reverse phase HPLC method has been developed and validated for the simultaneous determination of rosuvastatin calcium and amlodipine besylate at 240 nm in combined tablet dosage form and has been applied successfully for *in vitro* dissolution studies.

Rosuvastatin, chemically described as bis \[(E)-7 \[4-(4-fluorophenyl)-6 isopropyl-2\[methyl (methyl-sulphonyl) amino\] pyrimidin-5-yl\] (3R, 5S) -3, 5-dihydroxyhept-6-enoic acid\] ([Fig. 1](#f0005){ref-type="fig"}), is another member of the drug class statin. It is hydrophilic and this makes it hepatoselective. This drug may thus be considered as a substitute of atorvastatin to formulate a new combination of drug for dose-related reduction in systolic blood pressure, diastolic blood pressure and low density lipoprotein cholesterol in patients with co-morbid hypertension and dyslipidemia. It competitively inhibits HMG-CoA reductase enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis ([@b0045]).

Amlodipine besylate, chemically described as 3-ethyl-5-methyl(±)-2-\[(2-aminoethoxy)methyl\]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5 pyridinedicarboxylate, monobenzenesulphonate ([Fig. 2](#f0010){ref-type="fig"}), is a long-acting dihydropyridine class of calcium channel blocker, approved for treating hypertension and both vasospastic and chronic, stable angina ([@b0020]). It selectively inhibits the transmembrane influx of Ca^2+^ ion across L-type calcium channels, without changing serum calcium concentration. Thus it relaxes the muscles lining the arteries and lowers blood pressure. It also expands coronary arterioles which increases the flow of blood to the heart and prevents heart pain (angina) resulting from reduced flow of blood to the heart that is caused by coronary artery spasm (contraction). It is more vasoselective with lower negative inotropic effects and reflex tachycardia is less prominent since fluctuations in plasma levels are less pronounced with these agents ([@b0025]).

3. Materials and methods {#s0015}
========================

The present research started with the development of a proposed combination formulation of a statin with a calcium channel blocker. Excipients, used for the preparation of the combined formulation tablets of rosuvastatin and amlodipine, were initially chosen on the basis of the existing formulation of atorvastatin and amlodipine and their compatibility with the active ingredients verified using FTIR study. When the results came positive, the proposed formulation of the statin with the calcium channel blocker was adopted as the combination formulation and this was further studied. An assay based method was then developed and validated for the simultaneous estimation of rosuvastatin and amlodipine from the combination formulation which has been used further to characterize the *in vitro* dissolution profile of rosuvastatin calcium and amlodipine besylate.

3.1. Chemical and pharmaceutical preparation {#s0020}
--------------------------------------------

Reference standard of rosuvastatin calcium and amlodipine besylate was donated by the two of the leading local pharmaceutical companies of Bangladesh, Square Pharmaceuticals Limited, Bangladesh and Eskayef Bangladesh Limited, which are certified to be 96.36% and 99.33% pure respectively. The test tablets of the combination formulation of 10 mg rosuvastatin calcium and 5 mg amlodipine besylate used were manufactured in-house. The excipients needed to make the tablets were gifted from Eskayef Bangladesh Limited and ACI Limited. The commercially available preparation of rosuvastatin (label claim rosuvastatin calcium INN equivalent to rosuvastatin 10 mg) and amlodipine (label claim 5 mg amlodipine) used in the analysis, were collected from the local market. The water used for the preparation of buffer was purified by distillation. All the solvents used for the study were of HPLC grade.

3.2. Instrumentation {#s0025}
--------------------

The HPLC system consisted of a high pressure binary gradient pump (LC-20AT; Shimadzu), SIL-20AHT auto sampler, CTO-10ASvp column temperature oven, SPD-M20A PDA detector has been used for doing all the experiments including the development and its subsequent validation. All the components of the system are controlled by using CBM-20 Alite system controller. Data acquisition was done using lab solution LC workstation multi PDA software. The dissolution test was carried out using Universal Dissolution Tester (model: UDT 804-B).

3.3. Compatibility studies {#s0030}
--------------------------

The drug-excipient compatibility studies were done to select the excipients that are physically and chemically compatible with the API, using Fourier Transform Infrared spectroscopy. This was done by separately mixing each drug entity with the individual excipient in the ratio of 1:1. A separate FT-IR study of the standard sample of rosuvastatin calcium and amlodipine besylate was also done. The IR spectrum exhibiting the transmittance of different functional groups of the pure sample of rosuvastatin and amlodipine within 4000--400 cm^−1^ region was checked, studied and recorded ([Figure 3](#f0015){ref-type="fig"}, [Figure 4](#f0020){ref-type="fig"}) and their comparison with the IR spectrum exhibiting transmittance of those same functional groups was done in presence of each of the excipients individually ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}).

3.4. HPLC method {#s0035}
----------------

A reversed phase HPLC system was used to analyze both compounds with a sufficient separation and a fine peak shape owing to the relatively nonpolar properties of rosuvastatin calcium and amlodipine besylate. Therefore, all the experiments were carried out on a Luna 5μ C18 column (250 mm × 4.60 mm) at ambient temperature using different conditions of various mobile phases systematically. The mobile phase systems that were initially fixed after extensive literature review, focusing on the gradient elution of rosuvastatin and amlodipine, are as follows:(i)Phosphate buffer (pH 2.5): acetonitrile in the ratio 55:45% v/v ([@b0010]).(ii)Acetonitrile: THF: water at pH 3 in the ratio 68:12:20% v/v ([@b0065]).

The suitable wavelength for detection of rosuvastatin calcium and amlodipine besylate was selected from the overlain spectrum of rosuvastatin and amlodipine.

3.5. Preparation of solutions for assay {#s0040}
---------------------------------------

### 3.5.1. Standard preparation {#s0045}

Standard stock solution of rosuvastatin and amlodipine was prepared by dissolving 25 mg rosuvastatin and 12.5 mg amlodipine respectively with a small quantity of mobile phase into a clean dry 100 ml volumetric flask. It was then sonicated for 20 min and the final volume of the solution was then made up to 100 ml with the mobile phase. 4 ml solution was taken into 100 ml volumetric flask to obtain a concentration of 10 μg/ml rosuvastatin and 5 μg/ml amlodipine.

### 3.5.2. Sample preparation {#s0050}

A total of 20 tablets were accurately weighed and powdered in a clean dry mortar. An amount equivalent to 10 mg of rosuvastatin and 5 mg of amlodipine was taken in a conical flask and dissolved in small quantity of mobile phase with the aid of ultrasonication for 15 min. The resultant solution was then filtered, through Whatman filter paper, into a clean, dry 100 ml volumetric flask and the final volume was made up to 100 ml with the mobile phase. From the solution, 1 ml was taken out into 10 ml volumetric flask and dilution was done with the mobile phase to get a concentration of 10 μg/ml rosuvastatin and 5 μg/ml amlodipine. From this solution further dilutions were done and injected into the system to get the chromatogram.

3.6. Method validation {#s0055}
----------------------

The suggested RP-HPLC method was validated with respect to the corresponding parameters such as linearity, accuracy, precision, sensitivity, ruggedness, and robustness according to USP and ICH guidelines.

3.7. In-vitro dissolution study {#s0060}
-------------------------------

The *in vitro* dissolution study of the combined formulation of rosuvastatin calcium and amlodipine besylate, was carried out using USP-type II dissolution test apparatus. The drug release study was conducted using two different dissolution media to ascertain their percentage of release according to the respective dissolution profile mentioned in FDA reports. For the study of dissolution profile of rosuvastatin, 900 ml 0.05 M sodium citrate buffer of pH 6.6 was used as the dissolution medium where agitation speed of 50 rpm was maintained at (37 ± 0.5) °C for 60 min; and for amlodipine 500 ml 0.01 N HCl was used as dissolution medium with agitation speed of 75 rpm, maintained also at temperature (37 ± 0.5) °C for 60 min. Aliquots of about 10 ml had been withdrawn after 10, 20, 30, 45 and 60 min and filtered. The filtrates were then finally filtered through 0.2 μ disk filter and prepared vials were analyzed with the validated RP-HPLC method for assay. The dissolution profile of the combination formulation tablets of rosuvastatin and amlodipine was compared with that of separate commercial preparations of amlodipine and rosuvastatin alone.

4. Result & discussion {#s0065}
======================

4.1. IR spectral analysis {#s0070}
-------------------------

The compatibility study of rosuvastatin calcium and amlodipine besylate with the selected excipients came out positive which enabled us to adopt the formula to formulate the combination dosage form.

4.2. Chromatographic conditions {#s0075}
-------------------------------

The mobile phase composition of phosphate buffer (pH 2.5) and acetonitrile in the ratio 55:45% v/v that was set at a flow rate of 1.5 ml/min was chosen because it was found optimal to resolve the peak at 240 nm with retention time 2.7 min and 6.08 min for amlodipine and rosuvastatin respectively ([Fig. 5](#f0025){ref-type="fig"}). 10 μl samples were injected at each run.

4.3. Method validation {#s0080}
----------------------

### 4.3.1. System suitability test {#s0085}

Freshly prepared samples of rosuvastatin calcium and amlodipine besylate were injected six times into the chromatographic system under the optimized chromatographic conditions to check all the important parameters such as column efficiency (theoretical plates), peak tailing, retention factor, and resolution. The % RSD for the peak area ([Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}) response was found to be less than 2%.

### 4.3.2. Linearity {#s0090}

The linearity of calibration curves was established by plotting a graph between concentrations versus corresponding peak area of the sample ([Figure 6](#f0030){ref-type="fig"}, [Figure 7](#f0035){ref-type="fig"}) and co-relation coefficient, slope and y-intercept were determined. Five different concentrations of sample solutions were prepared in the concentration range of 80%, 90%, 100%, 110%, and 120% from the standard stock solution of rosuvastatin calcium and amlodipine besylate and injected into the HPLC system. The detector response was found to be linear with 8 μg/ml to 1.2 μg/ml concentration of rosuvastatin calcium and the 4 μg/ml to 6 μg/ml concentration of amlodipine besylate. The co-relation coefficient was found to be 0.992 for rosuvastatin and 0.995 for amlodipine ([Table 5](#t0025){ref-type="table"}).

### 4.3.3. Accuracy {#s0095}

The accuracy of the assay method was evaluated with the recovery of the standards from excipients ([@b0065]). Accuracy was carried out at three concentrations i.e. 80%, 100% and 120% of the target concentration of both the drugs. The concentration of solutions were prepared and injected six times. The mean percentage of recovery ([Table 5](#t0025){ref-type="table"}) for both the drugs was found to range from 98% to 102% for both rosuvastatin and amlodipine which suggests the accuracy of the method for their simultaneous estimation.

### 4.3.4. Precision {#s0100}

The intraday and interday precisions were assessed by multiple sampling of homogenous sample of 10 μg/ml rosuvastatin calcium and of 5 μg/ml amlodipine besylate. The percentage relative standard deviation ([Table 5](#t0025){ref-type="table"}) was found to be less than 2% for both interday and intra-day precision ([@b0050]).

### 4.3.5. Ruggedness {#s0105}

Ruggedness was determined by verifying the percentage relative standard deviation of the measurement of the two analysts in the same laboratory. For this purpose, six replicate samples were analyzed. The percentage relative standard deviation (%RSD) was found to be less than 2% for both the drugs ([Table 5](#t0025){ref-type="table"}).

### 4.3.6. Sensitivity {#s0110}

Limit of detection (LOD) and limit of quantitation (LOQ) were estimated from the signal-to-noise ratio ([@b0035]). Limit of detection is defined as the lowest concentration of analyte resulting in a peak area three times that of the baseline noise ([@b0035]). On the other hand, the limit of quantitation is defined as lowest concentration of analyte that provide a peak area that of ten times the baseline noise ([@b0035]). The LOD value for rosuvastatin calcium and amlodipine besylate was found to be 0.06 μg/ml and 0.018 μg/ml and the LOQ value for rosuvastatin calcium and amlodipine besylate was found to be 0.095 μg/ml and 0.22 μg/ml respectively ([Table 5](#t0025){ref-type="table"}).

### 4.3.7. Robustness {#s0115}

The robustness of an analytical procedure was assessed by measuring its capacity to remain unaffected by small but deliberate variations in method parameters which provides an indication of its reliability for routine analysis ([@b0050]). To determine robustness of the proposed method, test samples were prepared and analyzed by varying analytical parameters while keeping the other parameters unchanged such as the composition of mobile phase (±5%), flow rate (±2%), column temperature (±5 °C), and wavelength (±5). None of the alteration caused a significant change in peak area, percentage of relative standard deviation, tailing factor and retention time ([@b0050]). The results are recorded in [Table 6](#t0030){ref-type="table"}.

### 4.3.8. In vitro dissolution study {#s0120}

A typical acceptance criterion for dissolution release of drugs from immediate release tablet is about 80% of label amount in 45 min ([@b0070]). Both preparations (market and the combination formulation) were found to release an average of 95% rosuvastatin and 93% of amlodipine within 45 min ([Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}), without showing any hindrance to the release pattern of other drug ([Fig. 8](#f0040){ref-type="fig"}). The dissolution pattern complies with the BP Guidance standards as well as with the in-house specifications (rosuvastatin calcium is an INN drug), indicating suitability of the proposed method for the dissolution study of the two drugs (see [Fig. 9](#f0045){ref-type="fig"}).

5. Conclusion {#s0125}
=============

The proposed combination formulation of rosuvastatin calcium and amlodipine besylate has shown compatibility with the chosen excipients, verified through FT-IR study. A novel gradient RP-HPLC method was developed and validated according to the ICH guideline which was found to be suitable for the simultaneous estimation rosuvastatin calcium and amlodipine besylate from the combination formulation. The retention time of 2.7 and 6.08 min allows the analysis of large amount of samples with less mobile phase which makes the method economic. The dissolution profiles of both the drugs in different dissolution medium were encouraging which makes the combination formulation of rosuvastatin calcium and amlodipine besylate superior and effective in achieving patient compliance. The complete design of the study done can be depicted in a flowchart as shown in [Fig. 9](#f0045){ref-type="fig"}.
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###### 

FT-IR study of rosuvastatin calcium (standard) and its comparison with the mixed sample of rosuvastatin calcium and individual excipient.

                                         O---H stretching   Dual response   S000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O stretching   
  -------------------------------------- ------------------ --------------- ----------------------------------------------------------------------------------------------------------------------------------- ---------
  Rosuvastatin calcium (standard)        3420.87            2969.55         2928.04                                                                                                                             1156.36
  RSV + pregelatinized modified starch   3420.87            2968.55         2931.90                                                                                                                             1155.40
  RSV + microcrystalline cellulose       3420.87            2966.62         2930.93                                                                                                                             1156.36
  RSV + sodium starch glycolate          3440.16            2968.55         2930.93                                                                                                                             1155.40
  RSV + colloidal SiO~2~                 3433.41            2969.51         2934.79                                                                                                                             1113.93
  RSV + butylated hydroxyanisole         3421.83            2952.15         2915.5                                                                                                                              1156.36
  RSV + magnesium stearate               3428.76            2956.97         2916.47                                                                                                                             1156.36

###### 

FT-IR study of amlodipine besylate (standard) and its comparison with the mixed sample of amlodipine besylate and individual excipients.

                                                  N---H stretching   N---H stretching   C---H stretching   CO stretching   SO stretching
  ----------------------------------------------- ------------------ ------------------ ------------------ --------------- ---------------
  Amlodipine besylate (standard)                  3300.31            3157.58            3069.81            1696.45         1125.5
  AMD besylate + pregelatinized modified starch   3285.85            3155.65            3066.92            1696.45         1125.5
  AMD besylate + microcrystalline cellulose       3420.91            3169.15            3066.92            1696.45         1125.5
  AMD besylate + sodium starch glycolate          3291.63            3155.65            3083.31            1696.45         1125.50
  AMD besylate + colloidal SiO~2~                 3290.76            3155.67            3085.61            1696.45         1125.5
  AMD besylate + butylated hydroxyanisole         3329.25            3154.68            3068.85            1696.45         1125.5
  AMD besylate + Mg stearate                      3292.60            3164.33            3066.92            1696.45         1125.50

###### 

System suitability study of rosuvastatin calcium.

            Rosuvastatin calcium                     
  --------- ---------------------- ------- --------- -------
  Average   1.153                  6359    140,766   6.187
  STD       0.017                  36.73   33.13     0.006
  RSD (%)   1.45                   0.578   0.024     0.089

###### 

System suitability study of amlodipine besylate.

            Amlodipine besylate                      
  --------- --------------------- -------- --------- -------
  Average   1.035                 10,737   160,458   2.594
  STD       0.003                 18.97    313.42    0.002
  RSD (%)   0.28                  0.177    0.195     0.082

###### 

Linearity, accuracy, precision, ruggedness, LOD, and LOQ study of rosuvastatin calcium and amlodipine besylate.

  Validation parameters                 (Rosuvastatin calcium)                Amlodipine besylate                                        
  ------------------------------------- ------------------------------------- ----------------------------- ---------------------------- ---------
  Linearity                             Linear equation                       *y* = 16237620*x* − 3055.68   *y* = 12563120*x* + 1103.8   
  Correlation coefficient (*R*^2^)      0.992949109                           0.995915782                                                
  Accuracy                              \% of recovery                        80%                           102.88%                      102.88%
  100%                                  101.97%                               101.97%                                                    
  120%                                  98.67%                                98.67%                                                     
  Precision                             Interday precision peak area (%RSD)   0.099                         0.222                        
  Intraday precision peak area (%RSD)   0.099                                 0.149                                                      
  Ruggedness                            Peak area (%RSD)                      Analyst 1                     1.187                        1.187
  Analyst 2                             1.20                                  1.20                                                       
  LOD                                   Concentration (μg/ml)                 0.06                          0.018                        
  LOQ                                   Concentration (μg/ml)                 0.22                          0.095                        

###### 

Robustness study of rosuvastatin calcium and amlodipine besylate.

  Conditions                   Retention time   Peak area   Tailing factor   
  ---------------------------- ---------------- ----------- ---------------- -------
  *Rosuvastatin calcium*                                                     
  ACN:Buffer (48:52)           8.285            158,392     0.224            1.060
  ACN:Buffer (42:58)           5.166            155,370     0.076            1.023
  Flow rate (1.3 ml/min)       6.356            72,352      0.04             1.045
  Flow rate (1.7 ml/min)       5.654            139,265     0.10             1.040
  Column temperature (20 °C)   6.495            157,389     0.075            1.042
  Column temperature (30 °C)   6.234            157,247     0.096            1.052
  Wavelength (235 nm)          6.315            157,443     0.151            1.045
  Wavelength (245 nm)          6.345            157,622     0.178            1.047
                                                                             
  *Amlodipine besylate*                                                      
  ACN:Buffer (48:52)           2.405            62,771      0.213            1.133
  ACN:Buffer (42:58)           3.411            62,786      0.098            1.203
  Flow rate (1.3 ml/min)       3.130            72,348      0.036            1.187
  Flow rate (1.7 ml/min)       2.431            55,437      0.084            1.169
  Column temperature (20 °C)   2.673            63,159      0.737            1.185
  Column temperature (30 °C)   2.799            63,432      0.124            1.189
  Wavelength (235 nm)          2.765            63,175      0.161            1.184
  Wavelength (245 nm)          2.759            63290.4     0.246            1.181

###### 

Dissolution profile of rosuvastatin calcium.

  Time interval            Dissolution media                        \% of drug release   
  ------------------------ ---------------------------------------- -------------------- -------
  *Rosuvastatin calcium*                                                                 
  After 10 min             0.05 M sodium citrate buffer of pH 6.6   88.03                83.89
  After 20 min             91.65                                    90.86                
  After 30 min             94.06                                    92.7                 
  After 45 min             96.99                                    94.07                
  After 60 min             98.5                                     98                   

###### 

Dissolution profile of amlodipine besylate.

  Time interval           Dissolution media   \% of drug release   
  ----------------------- ------------------- -------------------- -------
  *Amlodipine besylate*                                            
  After 10 min            0.01 N HCl          58.69                90.08
  After 20 min            71.56               92.16                
  After 30 min            83.62               98                   
  After 45 min            92.56               102                  
  After 60 min            99.65               105                  
